Tekmira
and
Pfizer will collaborate on evaluating Tekmira's stable nucleic acid-lipid particle (SNALP) technology to deliver siRNA molecules provided by Pfizer. Tekmira will be responsible for preparing the SNALP formulations, and Pfizer will evaluate the formulations in preclinical models.
SNALP technology encapsulates siRNAs in uniform lipid nanoparticles, which are effective in delivering RNAi therapeutics to disease sites in preclinical models, according to Tekmira. SNALP formulations are manufactured by a proprietary method that is robust, scalable, and highly reproducible, the firm adds.